CPRX Catalyst Pharmaceuticals, Inc.

2.17
+0.04  (2%)
Previous Close 2.13
Open 2.12
Price To book 5.04
Market Cap 181.82M
Shares 83,786,000
Volume 241,681
Short Ratio 1.39
Av. Daily Volume 1,239,070

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data met endpoints - March 15, 2017. Pivotal trial planned.
Firdapse
MuSK-antibody positive myasthenia gravis (MuSK-MG)
Phase 3 data due 2H 2017.
Firdapse
Congenital Myasthenic Syndromes (CMS)
Refusal to file letter reported on February 17, 2016. Announced that enrollment had commenced in second Phase 3 trial on December 15, 2016, with data and NDA resubmission due in 2017.
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)

Latest News

  1. Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium
  2. Catalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions in Life Sciences & Healthcare
  3. Investor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call
  4. Catalyst reports 1Q loss
  5. Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update
  6. Catalyst Pharmaceuticals Announces Poster Presentation of MuSK-MG clinical data at the 13th International Conference on Myasthenia Gravis and Related Disorders
  7. What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
  8. Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 11th, 2017
  9. Catalyst Pharmaceuticals and ZIOPHARM Oncology Bounce Up On FDA Phase News
  10. Financials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting Stability
  11. Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next
  12. Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
  13. Catalyst Pharma Neuromuscular Drug Succeeds In Study
  14. Here’s Why Traders Are Piling Into These Five Stocks
  15. Catalyst Pharma shares jump 22% premarket on news of positive trial results for rare disease
  16. Catalyst Pharma's neuromuscular drug succeeds in study
  17. Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse® in treating MuSK Antibody Positive Myasthenia Gravis
  18. Catalyst Pharmaceuticals to Present at the 29th Annual ROTH Conference
  19. Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Thursday, March 16th, 2017